GOSS Gossamer Bio Inc

In a report released today, Eliana Merle from UBS maintained a Buy rating on Gossamer Bio (GOSS - Research Report), with a price target of $8.00. The company's shares opened today at $1.79.According to TipRanks, Merle is an analyst with an average return of -4.6% and a 38.64% success rate. Merle covers the Healthcare sector, focusing on stocks such as IVERIC bio, uniQure, and Moderna.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Gossamer Bio with a $9.44 average price target, which is a 427.37% upside from current levels.
https://www.tipranks.com/news/blurbs/ubs-keeps-their-buy-rating-on-gossamer-bio-goss?utm_source=advfn.com&utm_medium=referral